| A critical assessment of 50 leading companies, their research, products, partners and performance.
|
Additional InformationA critical assessment of leading companies, their research, products, partners and performance
The biopharmaceutical R&D sector is taking an ever more important role in the minds of industry and investors. The potential to fundamentally alter treatment regimes and cure, rather than symptomatically treat, many life-threatening conditions grows greater, but questions remain:
- Who are the companies that are leading development in this critical area?
- What is their area of expertise?
- How substantial is their current product line-up or pipeline projects?
- With whom are they collaborating?
- How can you assess their strengths and weaknesses?
Who’s Developing What in Global Biopharmaceuticals? is a new 475 page management guide to 50 significant companies working in the field. From their structure, through collaboration and detailed pipeline evaluation, the report provides an unmatchable window to the future biopharmaceutical corporate environment.
Important areas covered, where available, for each company include:
- Key Personnel - List of key management
- Company Overview
- Milestones - Summary table of key events in the company’s history
- R&D Pipeline - Products/research by phase and indication
- Technology - Novel discovery/production technology platforms
- Agreements - Who’s working with whom? Important alliances identified
- Key Financial Data - Essential P&L/funding data
- Appraisal & Evaluation - A critical assessment of the company’s platform, pipeline and corporate environment
Answering key questions such as...
- With which major pharmaceutical companies is French company Evotec working, and on what?
- Optimer Pharmaceuticals has eight products in development - what stage are they at and for what are they indicated?
- What benefit has Astex Therapeutics’ Pyramid drug discovery platform brought to the company?
Affymax
Ambit Biosciences
Ambrx
Amylin Pharmaceuticals
Arana Therapeutics
ARCA biopharma
ARIUS Research
ARYx Therapeutics
Astex Therapeutics
BioVex
BioXell
Bruin Pharmaceuticals
Cellectis
CombinatoRx
Deltanoid Pharmaceuticals
Diatos
Evotec
FivePrime Therapeutics
Genmab A/S
Idenix Pharmaceuticals
Ikaria
Infinity Pharmaceuticals
Intercytex
Ironwood Pharmaceuticals
KAI Pharmaceuticals
Kalypsys
Kereos
Micromet
Molecular Insight Pharmaceuticals
Neuromed Pharmaceuticals
Novexel
NPS Pharmaceuticals
Optimer Pharmaceuticals
Palatin Technologies
PharmaMar
Prana Biotechnology
Replidyne
S*BIO
Sosei
Speedel Pharmaceuticals
Synta Pharmaceuticals
Syntaxin
Takara Bio
Theravance
Tranzyme Pharma
Trimeris
Trubion Pharmaceuticals
ViroPharma
WILEX
Xencor
- AFFYMAX
- Key Personnel
- Company Overview
- Milestones
- R&D Pipeline
- Affymax R&D Pipeline, August 2008
- Haematology
- Hematide
- Other Indications
- Innotide
- Adeptide
- Angiotide
- Technology
- Agreements
- Takeda
- Entremed
- Nektar
- Key Financial Data
- Appraisal & Evaluation
- Platform, Pipeline, Products
- Corporate Environment
- AMBIT BIOSCIENCES
- Key Personnel
- Company Overview
- Milestones
- R&D Pipeline
- Ambit Biosciences R&D Pipeline, August 2008
- Oncology
- AC220
- AC480
- AURORA Kinase Inhibitors
- BRAF Kinase Inhibitors
- JAK2
- ABL (T3 151)
- Technologies
- Kinase Profiling Platform
- Agreements
- Cephalon
- bristol-myers squibb
- medarex
- AstraZeneca
- GlaxosmithKline
- Roche
- Pfizer
- Key Financial Data
- Appraisal & Evaluation
- Platform, Pipeline, Products
- Corporate Environment
- AMBRX
- Key Personnel
- Company Overview
- Milestones
- R&D Pipeline
- Human Growth Hormone
- ARX201
- Technologies
- ReCODE Technology
- Patents
- Agreements
- merck serono
- Eli Lilly
- Roche
- merck & Co
- Key Financial Data
- Appraisal & Evaluation
- Platform, Pipeline, Products
- Corporate Environment
- AMYLIN PHARMACEUTICALS
- Key Personnel
- Company Overview
- Milestones
- Marketed Products
- metabolism
- BYETTA (exenatide, AC2993 (synthetic exendin-4)) injection
- SYMLIN (pramlintide acetate) injection
- R&D Pipeline
- Amylin Pharmaceuticals R&D Pipeline, August 2008
- metabolism
- Diabetes
- Obesity
- Discontinued Products
- Cardiology
- AC3056
- AC2592
- Agreements
- Eli Lilly
- Alkermes
- Nastech
- PsychoGenics
- Kelaroo
- bioseek
- xenome
- Johnson & Johnson
- Aventis
- Key Financial Data
- Appraisal & Evaluation
- Platform, Pipeline, Products
- Corporate Environment
- ARANA THERAPEUTICS
- Key Personnel
- Company Overview
- Milestones
- R&D Pipeline
- Arana Therapeutics R&D Pipeline, August 2008
- Autoimmune and Inflammatory Diseases
- ART621
- PMX53
- Oncology
- ART104
- ART010
- ART150
- ART140
- ART101
- ART160
- Technologies
- Protein Engineering Platforms
- Patents
- Patent Families - Revenue Generating
- Patent Families - Product Development
- Agreements
- Vegenics
- AVEO Pharmaceuticals
- CsL Limited
- GlaxosmithKline
- Centocor
- Abbott
- EvoGenix Pty
- Kyowa Hakko
- greenovation biotech
- Key Financial Data
- Appraisal & Evaluation
- Platform, Pipeline, Products
- Corporate Environment
- ARCA BIOPHARMA
- Key Personnel
- Company Overview
- Milestones
- R&D Pipeline
- Cardiology
- Bucindolol
- Agreements
- Laboratory Corporation of America Holdings
- Key Financial Data
- Appraisal & Evaluation
- Platform, Pipeline, Products
- Corporate Environment
- ARIUS RESEARCH
- Key Personnel
- Company Overview
- Milestones
- R&D Pipeline
- ARIUS Research R&D Pipeline, August 2008
- Oncology
- CD44 Cancer Stem Cell Program/ARH460-16-2
- Trop-2 Signal Transduction Program/AR47A6 4 2
- CD59 Complement Inhibitor Program/AR36A36 11 1
- CD9 Cancer Stem Cell Program/AR40A746 2 3
- AR7BD-33-11A
- Others
- Technologies
- Patents
- Agreements
- Centro de Immunologia molecular (CImAb)
- xerion Pharmaceuticals AG
- PDL bioPharma
- medarex
- Oxford biomedica
- Genentech
- Takeda
- Key Financial Data
- Appraisal & Evaluation
- Platform, Pipeline, Products
- Corporate Environment
- ARYX THERAPEUTICS
- Key Personnel
- Company Overview
- Milestones
- R&D Pipeline
- ARYx Therapeutics R&D Pipeline, August 2008
- Gastrointestinal
- ATI-7505
- ATI-24,000
- Cardiology
- ATI-5923
- ATI-2042
- Antipsychotic
- ATI-9242
- metabolism
- ATI-20,000
- Technologies
- Drug Design Technology
- Design and Synthesis of Ideal Metabolites
- RetroMetabolic Engineering
- Evaluation of Metabolism
- Patents
- Agreements
- Procter & Gamble
- Key Financial Data
- Appraisal & Evaluation
- Platform, Pipeline, Products
- Corporate Environment
- ASTEX THERAPEUTICS
- Key Personnel
- Company Overview
- Milestones
- R&D Pipeline
- Astex Therapeutics R&D Pipeline, August 2008
- Oncology
- AT7519
- AT9283
- AT9311
- AT13387
- AT13148
- Technologies
- Drug Discovery Platform
- PYRAMID
- Patents
- Agreements
- Technology
- Cambridge Crystallographic Data Centre
- Daresbury Analytical Research and Technology Service
- Global Phasing
- Rigaku/MSC
- Daylight Chemical Information Systems
- Maybridge
- Product
- Janssen Research Foundation
- Aventis
- Mitsubishi Pharma
- AstraZeneca
- Institute of Cancer Research and Cancer Research Technology
- The Wellcome Trust, the Institute of Cancer Research, Cancer Research Technology and GlaxoSmithKline
- Schering AG
- Fujisawa Pharmaceutical
- Boehringer Ingelheim
- Novartis
- Pfizer
- University of Newcastle upon Tyne/Cancer Research Technology
- GlaxoSmithKline
- Janssen Pharmaceutica
- Key Financial Data
- Appraisal & Evaluation
- Platform, Pipeline, Products
- Corporate Environment
- BIOVEX
- Key Personnel
- Company Overview
- Milestones
- R&D Pipeline
- BioVex R&D Pipeline, August 2008
- Oncology
- OncoVEX GM-CSF
- Virology
- ImmunoVEXHSV2
- Patents
- Agreements
- Wyeth Pharmaceuticals
- merck & Co
- National Institutes of Health
- Key Financial Data
- Appraisal & Evaluation
- Platform, Pipeline, Products
- Corporate Environment
- BIOXELL
- Key Personnel
- Company Overview
- Milestones
- R&D Pipeline
- BioXell R&D Pipeline, August 2008
- urology
- BXL628/Elocalcitol
- Pain Relief
- MNAC13
- musculoskeletal
- BXL093
- Inflammation
- TREM-1
- TREM Programme
- BXL746
- Technologies
- The VD3 platform
- mNAC13 Platform
- The TREm platform
- Agreements
- Roche
- Lay Line Genomics
- merck & Co
- Galapagos/Proskelia
- Zambon
- Key Financial Data
- Appraisal & Evaluation
- Platform, Pipeline, Products
- Corporate Environment
- BRUIN PHARMACEUTICALS
- Key Personnel
- Company Overview
- R&D Pipeline
- Cardiology
- D-4F
- Key Financial Data
- Appraisal & Evaluation
- Platform, Pipeline, Products
- Corporate Environment
- CELLECTIS
- Key Personnel
- Company Overview
- Milestones
- R&D Pipeline
- Oncology
- Meganucleases targeting p53
- Meganucleases targeting XPC
- Immunology
- Meganuclease targeting IL2RG
- Meganuclease targeting RAG1
- Patents
- Agreements
- Artemis Pharmaceuticals
- Deltagen
- Nucleis
- fermentas
- Diversa
- Regeneron Pharmaceuticals
- murinus
- Ascenion
- Lexicon Genetics
- Celliance
- xenogen biosciences
- Ozgene
- biogen Idec
- AstraZeneca
- shire Pharmaceuticals
- Celonic
- Genentech
- GlaxosmithKline
- Laboratoires servier
- TransGenic
- Key Financial Data
- Appraisal & Evaluation
- Platform, Pipeline, Products
- Corporate Environment
- COMBINATORX
- Key Personnel
- Company Overview
- Milestones
- R&D Pipeline
- CombinatoRx R&D Pipeline, August 2008
- Immuno-inflammatory
- CRx-102
- CRx-139
- Pain
- CRx-170
- Dermatology
- CRx-191
- CRx-197
- metabolism
- CRx-401
- Other Research Programmes
- Technologies
- Drug Discovery Platforms
- Patents
- Agreements
- sosei
- Accelerate brain Cancer Cure (AbC2)
- The National Institutes of Allergy and Infectious Diseases
- HenKan Pharmaceutical Company
- Angiotech Pharmaceuticals
- bio*One Capital
- fovea Pharmaceuticals sA
- Cystic fibrosis foundation Therapeutics
- Cure Huntington's Disease Initiative
- Charley’s fund/The Nash Avery foundation
- spinal muscular Atrophy foundation (smA foundation)
- sAIC - National Institute of Neurological Disorders and stroke
- Key Financial Data
- Appraisal & Evaluation
- Platform, Pipeline, Products
- Corporate Environment
- DELTANOID PHARMACEUTICALS
- Key Personnel
- Company Overview
- Milestones
- R&D Pipeline
- Osteoporosis
- 2MD
- Agreements
- Abbott
- Key Financial Data
- Appraisal & Evaluation
- Platform, Pipeline, Products
- Corporate Environment
- DIATOS
- Key Personnel
- Company Overview
- Milestones
- R&D Pipeline
- Diatos R&D Pipeline, August 2008
- Oncology
- DaunoXome
- DTS-301
- DTS-201
- DTS-108
- Technologies
- Drug Development Platforms
- Agreements
- Gilead sciences
- macromed
- medarex
- université catholique de Louvain
- Institut Pasteur
- servier
- OctoPlus Technologies
- Key Financial Data
- Appraisal & Evaluation
- Platform, Pipeline, Products
- Corporate Environment
- EVOTEC
- Key Personnel
- Company Overview
- Milestones
- R&D Pipeline
- Evotec R&D Pipeline, August 2008
- Central Nervous system
- EVT 201
- EVT 101
- EVT 103
- EVT 302
- VR1 Antagonist Programme
- P2X3 and P2X2/3 Antagonist Programme
- B1 antagonists
- H3 antagonists
- BACE inhibitors
- Inflammatory Disease
- P2X7 Antagonist Programme
- MK2 inhibitors
- Oncology
- Hsp90 inhibitors
- Bcl-2, Bcl-xL and Mcl-1 inhibitors
- Technologies
- High-throughput screening (HTs) Technology
- EVOlution platform
- Patents
- Agreements
- boehringer Ingelheim
- Roche
- Cure Huntingdon’s Disease Initiative (CHDI)
- Ono Pharmaceutical
- Intermune
- Takeda
- Interprotein Corporation
- Other Research Contracts
- Key Financial Data
- Appraisal & Evaluation
- Platform, Pipeline, Products
- Corporate Environment
- FIVEPRIME THERAPEUTICS
- Key Personnel
- Company Overview
- Milestones
- R&D Pipeline
- FivePrime Therapeutics R&D Pipeline, August 2008
- Oncology
- FP-1039
- FPT040
- FPA005
- FPT069
- metabolism
- FPT038
- Cardiology
- FPT033/FPT057
- Gastrointestinal
- FPT042/FPT046
- Immunology
- FPT025
- Technologies
- Drug Discovery Platforms
- Agreements
- Gene Logic
- biosite
- boehringer Ingelheim
- Centocor/Johnson & Johnson
- Pfizer
- Key Financial Data
- Appraisal & Evaluation
- Platform, Pipeline, Products
- Corporate Environment
- GENMAB A/S
- Key Personnel
- Company Overview
- Milestones
- R&D Pipeline
- Genmab R&D Pipeline, August 2008
- Oncology
- HuMax-CD4 (zanolimumab)
- HuMax-CD20 (ofatumumab)
- HuMax-EGFr (zalutumumab)
- R1507
- HuMax-IL8
- HuMax-CD38
- HuMax-CD32b
- Autoimmune/Anti-inflammatory
- HuMax-CD20 (ofatumumab)
- AMG 714
- HuMax-IL8
- HuMax-TAC
- Neurology
- HuMax-CD20 (ofatumumab)
- Dermatology
- HuMax-IL8
- HuMax-TAC
- Respiratory
- Roche 4
- Virology
- HuMax-HepC
- Transplant Rejection
- HuMax-TAC
- undisclosed Indications
- Roche 2
- Roche 3
- Technologies
- Antibody Discovery Engine
- Antibody Centre of Excellence
- UniBody
- Patents
- Agreements
- Amgen
- ACE biosciences
- bionomics
- Cytokine Pharmasciences
- Ganymed Pharmaceuticals
- GlaxosmithKline
- medarex
- merck serono
- Roche
- Key Financial Data
- Appraisal & Evaluation
- Platform, Pipeline, Products
- Corporate Environment
- IDENIX PHARMACEUTICALS
- Key Personnel
- Company Overview
- Milestones
- Marketed Products
- R&D Pipeline
- Idenix Pharmaceuticals R&D Pipeline, August 2008
- Virology
- IDX184
- IDX899
- IDX375
- IDX136/IDX316 Macrocyclic Protease Inhibitors
- Discontinued Products
- Valopicitabine/NM283
- Patents
- Agreements
- metabasis Therapeutics
- Novartis Pharma
- Key Financial Data
- Appraisal & Evaluation
- Platform, Pipeline, Products
- Corporate Environment
- IKARIA
- Key Personnel
- Company Overview
- Milestones
- Marketed Products
- R&D Pipeline
- Ikaria R&D Pipeline, August 2008
- Cardiology
- INOMax
- IK-1001
- Immunology
- Covox
- Other Research Programmes
- Key Financial Data
- Appraisal & Evaluation
- Platform, Pipeline, Products
- Corporate Environment
- INFINITY PHARMACEUTICALS
- Key Personnel
- Company Overview
- Milestones
- R&D Pipeline
- Infinity Pharmaceuticals R&D Pipeline, August 2008
- Oncology
- Retaspimycin
- IPI-493
- IPI-926
- Bcl-2 Protein Inhibitors
- Technologies
- Diversity Oriented synthesis Technologies
- Patents
- Agreements
- medImmune/AstraZeneca
- Novartis
- Amgen
- Johnson & Johnson
- Key Financial Data
- Appraisal & Evaluation
- Platform, Pipeline, Products
- Corporate Environment
- INTERCYTEX
- Key Personnel
- Company Overview
- Milestones
- R&D Pipeline
- Intercytex R&D Pipeline, August 2008
- Dermatology
- ICX-PRO (cyzact)
- VAVELTA
- ICX-TRC
- ICX-SKN
- Technologies
- Agreements
- baxter Healthcare
- The Automation Partnership
- Armed forces Institute of Regenerative medicine
- Key Financial Data
- Appraisal & Evaluation
- Platform, Pipeline, Products
- Corporate Environment
- IRONWOOD PHARMACEUTICALS
- Key Personnel
- Company Overview
- Milestones
- R&D Pipeline
- Ironwood Pharmaceuticals R&D Pipeline, August 2008
- Gastrointestinal
- MD-1100/linaclotide
- Cardiology
- MD-0727
- Agreements
- forest Laboratories
- Key Financial Data
- Appraisal & Evaluation
- Platform, Pipeline, Products
- Corporate Environment
- KAI PHARMACEUTICALS
- Key Personnel
- Company Overview
- Milestones
- R&D Pipeline
- KAI Pharmaceuticals, August 2008
- Cardiology
- KAI-9803
- KAI-1455
- Pain management
- KAI-1678
- Gamma PKC
- Ophthalmology
- Beta PKC
- Inflammatory Disease
- Theta PKC Inhibition
- Agreements
- sankyo
- bristol-myers squibb
- Key Financial Data
- Appraisal & Evaluation
- Platform, Pipeline, Products
- Corporate Environment
- KALYPSYS
- Key Personnel
- Company Overview
- Milestones
- R&D Pipeline
- Kalypsys R&D Pipeline, August 2008
- metabolism
- KD3010
- KD3020
- Pain
- KD7040
- Oncology
- KD5170
- Technologies
- Agreements
- merck & Co
- CV Therapeutics
- Los Alamos National Laboratory
- National Institutes of Health
- NovImmune
- Eidogen-sertanty
- Alcon
- Key Financial Data
- Appraisal & Evaluation
- Platform, Pipeline, Products
- Corporate Environment
- KEREOS
- Key Personnel
- Company Overview
- Milestones
- R&D Pipeline
- Kereos R&D Pipeline, August 2008
- Oncology
- KI-0001
- KI-100X
- KM-4419
- Cardiology
- KI-0002
- KI-1004
- Technologies
- Ligand-Targeted Emulsion Technologies
- Agreements
- Philips
- Lantheus medical Imaging (bristol-myers squibb medical Imaging)
- Dow Chemical
- Washington university
- Key Financial Data
- Appraisal & Evaluation
- Platform, Pipeline, Products
- Corporate Environment
- MICROMET
- Key Personnel
- Company Overview
- Milestones
- R&D Pipeline
- Micromet R&D Pipeline, August 2008
- BiTE Antibody Only Pipeline
- Oncology
- MT103/MEDI-538
- Adecatumumab (MT201)
- MT293 (D93/TRC093)
- MT110
- MT111
- MT228 (MORAb-028)
- bscEphA2xCD3
- muS110
- Antibodies targeting CD33 and MCSP
- Inflammatory/Autoimmune Diseases
- MT203
- MT204
- Technologies
- biTE (bispecific T-Cell Engagers) Technology
- single Chain Antibodies
- Patents
- Agreements
- Enzon Pharmaceuticals
- Abbott, Alligator bioscience Ab, Haptogen and A N Other
- Cambridge Antibody Technology (CAT)
- EsbATech AG
- medImmune
- serono
- EvoGenix Pty
- Novuspharma spA
- TRACON Pharmaceuticals
- morphotek
- Nycomed
- university of southern California
- Applied molecular Evolution/Eli Lilly
- Arizeke Pharmaceuticals
- Antigenics
- Viventia barbados
- Key Financial Data
- Appraisal & Evaluation
- Platform, Pipeline, Products
- Corporate Environment
- MOLECULAR INSIGHT PHARMACEUTICALS
- Key Personnel
- Company Overview
- Milestones
- R&D Pipeline
- Molecular Insight R&D Pipeline, August 2008
- Oncology
- Azedra
- Onalta
- Solazed
- Trofex
- Cardiology
- Zemiva
- MIP-190
- Neurology
- MIP-170D
- Technologies
- ultratrace Technology
- sAAC Technology
- sAACQ Technology
- Nanotrace Discovery
- Patents
- Agreements
- bayer schering Pharma
- Novartis Pharma
- Key Financial Data
- Appraisal & Evaluation
- Platform, Pipeline, Products
- Corporate Environment
- NEUROMED PHARMACEUTICALS
- Key Personnel
- Company Overview
- Milestones
- R&D Pipeline
- Neuromed Pharmaceuticals Pipeline, August 2008
- Pain
- NMED-160
- NMED-1077
- Others
- Other Indications
- Agreements
- merck & Co
- Key Financial Data
- Appraisal & Evaluation
- Platform, Pipeline, Products
- Corporate Environment
- NOVEXEL
- Key Personnel
- Company Overview
- Milestones
- R&D Pipeline
- Novexel R&D Pipeline, August 2008
- Antibacterial
- NXL103
- NXL101
- NXL104
- NXL105
- Antifungal
- NXL201
- Agreements
- Indevus Pharmaceuticals
- forest Laboratories
- Key Financial Data
- Appraisal & Evaluation
- Platform, Pipeline, Products
- Corporate Environment
- NPS PHARMACEUTICALS
- Key Personnel
- Company Overview
- Milestones
- R&D Pipeline
- NPS Pharmaceuticals R&D Pipeline, August 2008
- Gastrointestinal
- GATTEX
- musculoskeletal
- PREOS/Preotact
- calcilytics
- Central Nervous system
- NPSP156
- metabolism
- NPSP558 (parathyroid hormone 1-84 [rDNA origin] injection)
- Renal
- Cinacalcet HCl
- Patents
- Agreements
- Amgen
- Kirin Pharma
- Nycomed
- DRI Capital
- GlaxosmithKline
- Janssen
- AstraZeneca
- Ortho-mcNeil Pharmaceuticals
- Key Financial Data
- Appraisal & Evaluation
- Platform, Pipeline, Products
- Corporate Environment
- OPTIMER PHARMACEUTICALS
- Key Personnel
- Company Overview
- Milestones
- R&D Pipeline
- Optimer Pharmaceuticals R&D Pipeline, August 2008
- Antibacterial
- OPT-80
- Prulifloxacin (OPT-99)
- OPT-1068/CEM-101
- musculoskeletal
- OPT-88
- Oncology
- OPT-822/OPT-821
- Technologies
- Drug Discovery Platform
- Patents
- Agreements
- C&O Pharmaceutical Technology (Holdings)
- Par Pharmaceutical
- biocon
- Nippon shinyaku
- sloan-Kettering Institute for Cancer Research
- Cempra Pharmaceuticals
- The scripps Research Institute
- Inc Research
- National Institute of Allergy and Infectious Diseases
- Key Financial Data
- Appraisal & Evaluation
- Platform, Pipeline, Products
- Corporate Environment
- PALATIN TECHNOLOGIES
- Key Personnel
- Company Overview
- Milestones
- R&D Pipeline
- Palatin Technologies R&D Pipeline, August 2008
- Cardiology
- Bremelanotide
- PL-6983
- Natriuretic Receptor Compounds/PL-3994
- metabolism
- Melanocortin-based Therapeutics
- Imaging/Diagnosis
- NeutroSpec
- Technologies
- Drug Development Platforms
- MIDAS Drug Development Platform
- NeutroSpec
- Patents
- Agreements
- AstraZeneca
- mallinckrodt
- Key Financial Data
- Appraisal & Evaluation
- Platform, Pipeline, Products
- Corporate Environment
- PHARMAMAR
- Key Personnel
- Company Overview
- Milestones
- R&D Pipeline
- PharmaMar R&D Pipeline, August 2008
- Oncology
- Yondelis (trabectedin)
- Aplidin (plitidepsin)
- PM02734
- Kahalalide F
- Zalypsis
- Thiocoraline
- Variolins
- Lamellarins
- Dermatology
- Kahalalide F
- Agreements
- Johnson & Johnson
- Innovex
- swedish Orphan International
- Genesis Pharma
- Cenit-Nanopharma Consortium
- Key Financial Data
- Appraisal & Evaluation
- Platform, Pipeline, Products
- Corporate Environment
- PRANA BIOTECHNOLOGY
- Key Personnel
- Company Overview
- Milestones
- R&D Pipeline
- Prana Biotechnology R&D Pipeline, August 2008
- Central Nervous system
- PBT2
- Drug Candidate
- Amyloid-inhibiting compounds
- Immunotherapy
- MAbs against Abeta
- Oncology
- PBT1/others
- Ophthalmology
- MPAC Compounds
- Discontinued Products
- Central Nervous system
- PBT1 (Clioquinol)
- Patents
- Agreements
- schering AG
- Australian Industry Research and Development board
- Key Financial Data
- Appraisal & Evaluation
- Platform, Pipeline, Products
- Corporate Environment
- REPLIDYNE
- Key Personnel
- Company Overview
- Milestones
- R&D Pipeline
- Replidyne R&D Pipeline, August 2008
- Antibacterial
- Faropenem medoxomil
- REP3123/REP8839
- DNA Replication Inhibitors Programme
- Patents
- Agreements
- forest Laboratories
- Asubio Pharma
- Key Financial Data
- Appraisal & Evaluation
- Platform, Pipeline, Products
- Corporate Environment
- S*BIO
- Key Personnel
- Company Overview
- Milestones
- R&D Pipeline
- Clinical Trials
- HDAC
- Kinase Programme
- S*BIO R&D Pipeline, 2008
- Technology
- Agreements
- A*sTAR
- Genome Institute of singapore
- Karolinska Institutet
- National university Hospital, singapore
- Key Financial Data
- Appraisal & Evaluation
- Platform, Pipeline, Products
- Corporate Environment
- SOSEI
- Key Personnel
- Company Overview
- Milestones
- R&D Pipeline
- Sosei R&D Pipeline, August 2008
- Respiratory system
- NVA237
- QVA149
- Oncology
- AD923
- Central Nervous system
- AD337
- SD118
- Inflammation and Immunology
- SD726
- SD208
- Women’s Healthcare
- SOH-075
- Agreements
- mundipharma
- sandoz
- CombinatoRx
- Key Financial Data
- Appraisal & Evaluation
- Platform, Pipeline, Products
- Corporate Environment
- SPEEDEL PHARMACEUTICALS
- Key Personnel
- Company Overview
- Milestones
- R&D Pipeline
- Speedel R&D Pipeline, August 2008
- Cardiology
- SPP100 (aliskiren,Tekturna, Rasilez)
- SPP200 (pegmusirudin)
- SPP301 (avosentan)
- SPP600
- SPP635
- SPP676
- SPP800 Series
- SPP1100 Series
- SPP2000 Series
- Agreements
- Locus Pharmaceuticals
- Novartis
- Roche
- Abbott Laboratories
- Key Financial Data
- Appraisal & Evaluation
- Platform, Pipeline, Products
- Corporate Environment
- SYNTA PHARMACEUTICALS
- Key Personnel
- Company Overview
- Milestones
- R&D Pipeline
- Synta Pharmaceuticals R&D Pipeline, August 2008
- Oncology
- STA-4783 (elesclomol)
- STA-9090
- STA-9584
- STA-5312
- Inflammatory Disease
- STA-5326 (apilimod mesylate)
- Crohn’s Disease
- Rheumatoid Arthritis
- Common Variable Immunodeficiency
- Psoriasis
- CRAC ion channel inhibitor
- Technologies
- Chemical Library
- screening Assays
- In vivo Testing Capabilities
- Chemistry Capabilities
- Target Elucidation
- Patents
- Agreements
- GlaxosmithKline
- Key Financial Data
- Appraisal & Evaluation
- Platform, Pipeline, Products
- Corporate Environment
- SYNTAXIN
- Key Personnel
- Company Overview
- Milestones
- R&D Pipeline
- Syntaxin R&D Pipeline, August 2008
- Pain
- Un-named Product
- Respiratory
- SYN187
- Other
- Endocrinology Products
- Obesity Products
- Nerve Disorder Products
- Agreements
- Allergan
- Key Financial Data
- Appraisal & Evaluation
- Platform, Pipeline, Products
- Corporate Environment
- TAKARA BIO
- Key Personnel
- Company Overview
- Milestones
- R&D Pipeline
- Oncology
- HSV-TK gene therapies
- T-cell receptor (TCR) gene therapy
- Cancer Immunotherapy
- Cancer Immunity Reconstruction Therapy
- Virology
- VRX496
- MazF Gene Therapy
- Technologies
- Research Reagents and scientific Instruments
- Contract Research services
- Agreements
- InVivoscribe Technologies
- memorial sloan-Kettering Cancer Center
- Peter macCallum Cancer Centre
- Green Cross Corporation
- New England biolabs
- Transgenomic
- Kemp biotechnologies
- Tianjin medical university
- Key Financial Data
- Appraisal & Evaluation
- Platform, Pipeline, Products
- Corporate Environment
- THERAVANCE
- Key Personnel
- Company Overview
- Milestones
- R&D Pipeline
- Theravance R&D Pipeline, August 2008
- Antibacterial
- Telavancin
- TD-1792
- Respiratory
- GW642444
- GW685698
- GSK159797
- GSK1160724
- GSK656398
- GSK961081
- Gastrointestinal
- TD-5108
- TD-2749
- TD-6301
- Patents
- Agreements
- Astellas
- GlaxosmithKline
- AstraZeneca
- Key Financial Data
- Appraisal & Evaluation
- Platform, Pipeline, Products
- Corporate Environment
- TRANZYME PHARMA
- Key Personnel
- Company Overview
- Milestones
- R&D Pipeline
- Tranzyme Pharma R&D Pipeline, August 2008
- Gastrointestinal
- TZP-101
- TZP-102
- TZP-201
- TZP-301
- Technologies
- Drug Discovery Platform
- Macrocyclic Template Chemistry (MATCH)
- Patents
- Agreements
- Neokimia/Trimeris
- Key Financial Data
- Appraisal & Evaluation
- Platform, Pipeline, Products
- Corporate Environment
- TRIMERIS
- Key Personnel
- Company Overview
- Milestones
- Marketed Products
- Virology
- FUZEON
- R&D Pipeline
- Virology
- FUZEON
- TRI-1144
- Patents
- Agreements
- Roche
- Array biopharma
- Neokimia/Tranzyme
- Chembridge Research Laboratories
- New york blood Center
- Key Financial Data
- Appraisal & Evaluation
- Platform, Pipeline, Products
- Corporate Environment
- TRUBION PHARMACEUTICALS
- Key Personnel
- Company Overview
- Milestones
- R&D Pipeline
- Trubion Pharmaceuticals R&D Pipeline, August 2008
- Autoimmune/Inflammatory Diseases
- TRU-015
- SBI-087
- Oncology
- TRU-015
- TRU-016
- Technologies
- Product Engine
- Patents
- Agreements
- Wyeth
- Key Financial Data
- Appraisal & Evaluation
- Platform, Pipeline, Products
- Corporate Environment
- VIROPHARMA
- Key Personnel
- Company Overview
- Milestones
- Marketed Products
- Antibacterial
- Vancocin
- R&D Pipeline
- ViroPharma R&D Pipeline, August 2008
- Virology
- Maribavir (CAMVIA)
- CDI Programme
- Anti-inflammatory
- C1 inhibitor (human)
- Discontinued Products
- Virology
- Picovir (Pleconaril)
- Hepatitis C Candidates
- HCV371
- HCV-086
- HCV-796
- Patents
- Agreements
- GlaxosmithKline
- sanofi-synthélabo/sanofi-aventis
- schering-Plough
- Eli Lilly
- Wyeth
- Key Financial Data
- Appraisal & Evaluation
- Platform, Pipeline, Products
- Corporate Environment
- WILEX
- Key Personnel
- Company Overview
- Milestones
- R&D Pipeline
- WILEX R&D Pipeline, August 2008
- Oncology
- WX-G250 and WX-G250RIT (RENCAREX)
- WX-UK1
- K931
- WX-671 (MESUPRON)
- CA9-SCAN (REDECTANE)
- WX-77X Series
- Patents
- Agreements
- Centocor
- bayer
- Vu university medical Center Amsterdam
- fox Chase Cancer Center
- Esteve
- IbA molecular
- Key Financial Data
- Appraisal & Evaluation
- Platform, Pipeline, Products
- Corporate Environment
- XENCOR
- Key Personnel
- Company Overview
- Milestones
- R&D Pipeline
- Xencor R&D Pipeline, August 2008
- Inflammatory Disease
- XPro1595
- Oncology
- XmAb2513
- Oncology/Inflammatory Disease
- XmAb5574
- XmAb5871
- XmAb5485
- Technologies
- Protein Design Automation
- xPro
- XmAb technology
- ImmunoPDA
- Patents
- Agreements
- Caltech
- Torrey mesa Research Institute
- Protein Design Labs
- Eli Lilly
- Genentech
- Chugai Pharmaceutical
- Centocor
- medImmune
- Roche
- boehringer Ingelheim
- Human Genome sciences
- Key Financial Data
- Appraisal & Evaluation
- Platform, Pipeline, Products
- Corporate Environment
- ESPICOM ANALYSIS
- Winners & Losers
- Biopharmaceutical Company R&D Pipelines
- Phase III Drug Candidates
- Phase III Drug Candidates
- Methodology
- Company Ratings
Share this report
Other tasks Related Markets Biopharmaceuticals Reports Free Alert Me service Receive bi-weekly email alerts on new market research Sign Up Today!
|
